Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011477
Filing Date
2025-08-14
Accepted
2025-08-14 08:08:35
Documents
69
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q xlo-20250630x10q.htm   iXBRL 10-Q 2176903
2 EX-3.1 xlo-20250630xex3d1.htm EX-3.1 80698
3 EX-31.1 xlo-20250630xex31d1.htm EX-31.1 13267
4 EX-31.2 xlo-20250630xex31d2.htm EX-31.2 13170
5 EX-32.1 xlo-20250630xex32d1.htm EX-32.1 7780
  Complete submission text file 0001558370-25-011477.txt   7576649

Data Files

Seq Description Document Type Size
6 EX-101.SCH xlo-20250630.xsd EX-101.SCH 53735
7 EX-101.CAL xlo-20250630_cal.xml EX-101.CAL 34179
8 EX-101.DEF xlo-20250630_def.xml EX-101.DEF 250311
9 EX-101.LAB xlo-20250630_lab.xml EX-101.LAB 436585
10 EX-101.PRE xlo-20250630_pre.xml EX-101.PRE 375022
72 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20250630x10q_htm.xml XML 1028648
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40925 | Film No.: 251214492
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)